Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDI Calidi Biotherapeutics	$5.01 -13.0%	$5.43	$2.43 ▼ $46.68	$15.16M	1.15	655,731 shs	164,927 shs
LENZ LENZ Therapeutics	$34.68 +8.0%	$31.26	$16.53 ▼ $38.93	$989.07M	0.42	417,189 shs	1.14 million shs
MLYS Mineralys Therapeutics	$13.00 +1.0%	$14.25	$8.24 ▼ $18.38	$847.34M	-0.29	696,773 shs	502,001 shs
ZYME Zymeworks	$12.02 -1.2%	$12.92	$9.03 ▼ $17.70	$837.59M	1.26	537,221 shs	872,724 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDI Calidi Biotherapeutics	0.00%	-29.27%	-45.07%	-5.93%	-76.01%
LENZ LENZ Therapeutics	0.00%	+15.75%	-0.03%	+18.08%	+45.84%
MLYS Mineralys Therapeutics	0.00%	-4.83%	-10.28%	-13.39%	+17.97%
ZYME Zymeworks	0.00%	-4.38%	-9.90%	0.00%	+18.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDI Calidi Biotherapeutics	0.232 of 5 stars	0.0	2.0	1.9	0.0	0.6
LENZ LENZ Therapeutics	1.6397 of 5 stars	3.6	0.0	3.7	0.8	0.0
MLYS Mineralys Therapeutics	2.1298 of 5 stars	3.4	1.0	1.8	4.2	0.0
ZYME Zymeworks	3.196 of 5 stars	3.5	4.0	3.1	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDI Calidi Biotherapeutics	0.00	N/A	N/A	N/A
LENZ LENZ Therapeutics	3.17	Buy	$49.60	43.02% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	148.08% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.00	74.71% Upside

Current Analyst Ratings Breakdown

Latest CLDI, MLYS, ZYME, and LENZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	LENZ LENZ Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $49.00
7/31/2025	LENZ LENZ Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
7/28/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $48.00
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
5/20/2025	ZYME Zymeworks	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	($2.32) per share	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.42 per share	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
ZYME Zymeworks	$122.87M	6.82	N/A	N/A	$6.63 per share	1.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
LENZ LENZ Therapeutics	-$49.77M	-$1.90	N/A	N/A	N/A	N/A	-25.63%	-24.43%	8/13/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$0.97	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	N/A

Latest CLDI, MLYS, ZYME, and LENZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.62	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	MLYS Mineralys Therapeutics	-$0.78	N/A	N/A	N/A	N/A	N/A
8/7/2025	N/A	ZYME Zymeworks	-$0.52	$0.03	+$0.55	N/A	$17.18 million	$48.73 million
7/30/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.58	-$0.53	+$0.05	-$0.53	$5.00 million	$5.00 million
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
LENZ LENZ Therapeutics	N/A	20.54	20.54
MLYS Mineralys Therapeutics	N/A	26.48	26.48
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDI Calidi Biotherapeutics	12.53%
LENZ LENZ Therapeutics	54.32%
MLYS Mineralys Therapeutics	84.46%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
CLDI Calidi Biotherapeutics	6.70%
LENZ LENZ Therapeutics	6.90%
MLYS Mineralys Therapeutics	33.24%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDI Calidi Biotherapeutics	38	3.03 million	20.04 million	N/A
LENZ LENZ Therapeutics	110	28.52 million	26.55 million	N/A
MLYS Mineralys Therapeutics	28	65.18 million	43.51 million	Optionable
ZYME Zymeworks	460	69.68 million	67.56 million	Optionable

CLDI, MLYS, ZYME, and LENZ Headlines

Recent News About These Companies

Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from Analysts

4 hours ago | marketbeat.com

Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 10 at 2:16 PM | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Given Consensus Rating of "Moderate Buy" by Analysts

August 10 at 2:17 AM | americanbankingnews.com

Zymeworks (NYSE:ZYME) Announces Earnings Results, Beats Expectations By $0.55 EPS

August 9 at 7:23 AM | marketbeat.com

Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression

August 8 at 7:30 PM | msn.com

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

August 8 at 5:06 PM | seekingalpha.com

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Zymeworks (ZYME) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and ...

July 30, 2025 | finance.yahoo.com

FDA Greenlights Trials of Novel ADC and Radiopharmaceutical in Solid Tumors

July 30, 2025 | targetedonc.comT

Zymeworks Inc.: Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

July 28, 2025 | finanznachrichten.de

Zymeworks Shares Climb After FDA Clears Investigational New Drug Application

July 28, 2025 | marketwatch.com

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

July 28, 2025 | globenewswire.com

Zymeworks (NYSE:ZYME) Trading 7% Higher - Should You Buy?

July 18, 2025 | marketbeat.com

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

July 18, 2025 | zacks.com

Zymeworks Inc. to Release Second Quarter 2025 Financial Results on August 7, 2025

July 17, 2025 | quiverquant.comQ

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17, 2025 | financialpost.comF

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17, 2025 | financialpost.comF

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDI, MLYS, ZYME, and LENZ Company Descriptions

Calidi Biotherapeutics NYSE:CLDI

$5.01 -0.75 (-13.02%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$5.34 +0.34 (+6.69%)

As of 05:00 AM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

LENZ Therapeutics NASDAQ:LENZ

$34.68 +2.56 (+7.97%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$40.50 +5.82 (+16.78%)

As of 05:16 AM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Mineralys Therapeutics NASDAQ:MLYS

$13.00 +0.13 (+1.01%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$13.32 +0.32 (+2.50%)

As of 08/8/2025 05:46 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Zymeworks NYSE:ZYME

$12.02 -0.14 (-1.15%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$11.96 -0.06 (-0.50%)

As of 05:15 AM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time